Response to Combination Cholinergic/Noradrenergic Treatments in a Patient With Alzheimer's Disease
Paul S Aisen1, Linda M Bierer1, Michael Davidson1
1Department of Psychiatry, Box 1230, Mt. Sinai Medical Center, 1 Gustave L. Levy PI., New York, NY 10029.
Abstract:
A patient with probable Alzheimer's disease participated in four studies involving cholinergic and combination cholinergic/noradrenergic treatment regimens. This patient demonstrated clinically significant improvement only with the combination of physostigmine and clonidine. The implications of these findings are discussed with regard to strategies for neurotransmitter augmentation therapy for Alzheimer's disease.
More Related Videos
05:54Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
Published on: May 10, 2024
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Related Concept Videos
Alzheimer's Disease: Treatment
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
